SK284059B6 - Spôsob prípravy substituovaných sulfoxidov - Google Patents

Spôsob prípravy substituovaných sulfoxidov Download PDF

Info

Publication number: SK284059B6
Authority: SK; Slovakia
Prior art keywords: mmol; het; chiral; sulfoxide; titanium
Prior art date: 1994-07-15

Application number

SK48-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK4897A3 (en

Inventor

Erik Magnus Larsson

Urban Jan Stenhede

Henrik S�RENSEN

Unge Per Oskar Sverker Von

Hanna Kristina Cotton

Original Assignee

Astra Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-07-03

Publication date

2004-09-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20394753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284059(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-07-03 Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag

1997-08-06 Publication of SK4897A3 publication Critical patent/SK4897A3/sk

2004-09-08 Publication of SK284059B6 publication Critical patent/SK284059B6/sk

Links

238000000034 method Methods 0.000 title claims abstract description 86
230000015572 biosynthetic process Effects 0.000 title abstract description 8
238000003786 synthesis reaction Methods 0.000 title abstract description 8
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims abstract description 59
238000007254 oxidation reaction Methods 0.000 claims abstract description 52
230000003647 oxidation Effects 0.000 claims abstract description 50
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 20
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 90
150000003462 sulfoxides Chemical class 0.000 claims description 85
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 48
VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical group CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 claims description 39
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 37
239000010936 titanium Substances 0.000 claims description 35
229910052719 titanium Inorganic materials 0.000 claims description 33
RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 30
239000000047 product Substances 0.000 claims description 29
FRIBMENBGGCKPD-UHFFFAOYSA-N 3-(2,3-dimethoxyphenyl)prop-2-enal Chemical compound COC1=CC=CC(C=CC=O)=C1OC FRIBMENBGGCKPD-UHFFFAOYSA-N 0.000 claims description 28
239000002585 base Substances 0.000 claims description 28
-1 sulfoxide compound Chemical class 0.000 claims description 28
238000002360 preparation method Methods 0.000 claims description 22
YSAVZVORKRDODB-PHDIDXHHSA-N diethyl (2r,3r)-2,3-dihydroxybutanedioate Chemical group CCOC(=O)[C@H](O)[C@@H](O)C(=O)OCC YSAVZVORKRDODB-PHDIDXHHSA-N 0.000 claims description 21
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 17
QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 17
235000011114 ammonium hydroxide Nutrition 0.000 claims description 17
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 13
230000035484 reaction time Effects 0.000 claims description 13
125000001424 substituent group Chemical group 0.000 claims description 13
125000000217 alkyl group Chemical group 0.000 claims description 12
229910052739 hydrogen Inorganic materials 0.000 claims description 12
239000001257 hydrogen Substances 0.000 claims description 12
239000003960 organic solvent Substances 0.000 claims description 12
239000002904 solvent Substances 0.000 claims description 12
239000012043 crude product Substances 0.000 claims description 10
150000002431 hydrogen Chemical class 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
125000003545 alkoxy group Chemical group 0.000 claims description 8
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical group 0.000 claims description 8
239000007800 oxidant agent Substances 0.000 claims description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
150000002009 diols Chemical class 0.000 claims description 4
239000003446 ligand Substances 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
150000003609 titanium compounds Chemical class 0.000 claims description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
150000001447 alkali salts Chemical class 0.000 claims description 2
125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
125000004414 alkyl thio group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
125000006165 cyclic alkyl group Chemical group 0.000 claims description 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 2
125000004663 dialkyl amino group Chemical group 0.000 claims description 2
229910052731 fluorine Inorganic materials 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
125000004438 haloalkoxy group Chemical group 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
150000007530 organic bases Chemical class 0.000 claims description 2
125000002971 oxazolyl group Chemical group 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000002071 phenylalkoxy group Chemical group 0.000 claims description 2
125000003884 phenylalkyl group Chemical group 0.000 claims description 2
125000004950 trifluoroalkyl group Chemical group 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical group CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims 3
150000002148 esters Chemical class 0.000 claims 2
HBDKFZNDMVLSHM-UHFFFAOYSA-N 2-(pyridin-2-ylmethylsulfinyl)-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)CC1=CC=CC=N1 HBDKFZNDMVLSHM-UHFFFAOYSA-N 0.000 abstract description 13
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract description 13
229960000381 omeprazole Drugs 0.000 abstract description 7
ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 abstract 2
159000000011 group IA salts Chemical class 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 description 115
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 87
150000001875 compounds Chemical class 0.000 description 61
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 60
230000003287 optical effect Effects 0.000 description 53
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 41
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
239000000243 solution Substances 0.000 description 36
238000011914 asymmetric synthesis Methods 0.000 description 31
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
238000007792 addition Methods 0.000 description 28
RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 26
150000003457 sulfones Chemical class 0.000 description 26
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
230000014759 maintenance of location Effects 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 19
238000004458 analytical method Methods 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
239000011541 reaction mixture Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 14
XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 description 13
YSAVZVORKRDODB-WDSKDSINSA-N diethyl tartrate Chemical compound CCOC(=O)[C@@H](O)[C@H](O)C(=O)OCC YSAVZVORKRDODB-WDSKDSINSA-N 0.000 description 13
238000001704 evaporation Methods 0.000 description 13
230000008020 evaporation Effects 0.000 description 13
150000003568 thioethers Chemical class 0.000 description 13
AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 12
235000019439 ethyl acetate Nutrition 0.000 description 12
239000010410 layer Substances 0.000 description 12
239000003480 eluent Substances 0.000 description 11
238000001914 filtration Methods 0.000 description 11
239000013078 crystal Substances 0.000 description 10
239000000706 filtrate Substances 0.000 description 10
239000002244 precipitate Substances 0.000 description 10
CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 10
238000002425 crystallisation Methods 0.000 description 9
230000008025 crystallization Effects 0.000 description 9
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
229910052717 sulfur Inorganic materials 0.000 description 9
125000004434 sulfur atom Chemical group 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
238000000605 extraction Methods 0.000 description 7
239000000741 silica gel Substances 0.000 description 7
229910002027 silica gel Inorganic materials 0.000 description 7
125000000446 sulfanediyl group Chemical group *S* 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
239000008346 aqueous phase Substances 0.000 description 6
238000004296 chiral HPLC Methods 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
ISRXMEYARGEVIU-UHFFFAOYSA-N n-methyl-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C)C(C)C ISRXMEYARGEVIU-UHFFFAOYSA-N 0.000 description 6
239000011734 sodium Substances 0.000 description 6
POQMHHDKXWTFHB-UHFFFAOYSA-N 1-[5-[(4,5-diphenyl-1h-imidazol-2-yl)sulfinyl]pentyl]-3,5-dimethylpyrazole Chemical compound N1=C(C)C=C(C)N1CCCCCS(=O)C1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 POQMHHDKXWTFHB-UHFFFAOYSA-N 0.000 description 5
PSIREIZGKQBEEO-UHFFFAOYSA-N 2-(1h-benzimidazol-2-ylsulfinylmethyl)-n-methyl-n-(2-methylpropyl)aniline Chemical compound CC(C)CN(C)C1=CC=CC=C1CS(=O)C1=NC2=CC=CC=C2N1 PSIREIZGKQBEEO-UHFFFAOYSA-N 0.000 description 5
DIUOJMLXZJHNDR-UHFFFAOYSA-N 2-[[4-(cyclopropylmethoxy)pyridin-2-yl]methylsulfinyl]-6-fluoro-1h-benzimidazole Chemical compound N=1C2=CC(F)=CC=C2NC=1S(=O)CC(N=CC=1)=CC=1OCC1CC1 DIUOJMLXZJHNDR-UHFFFAOYSA-N 0.000 description 5
HVAJOLFRLWQQQL-UHFFFAOYSA-N 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole;sodium Chemical compound [Na].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C HVAJOLFRLWQQQL-UHFFFAOYSA-N 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000010992 reflux Methods 0.000 description 5
KTXVWWXXGRAFKB-UHFFFAOYSA-N 2-[[4-(cyclopropylmethoxy)pyridin-2-yl]methylsulfanyl]-6-fluoro-1h-benzimidazole Chemical compound N=1C2=CC(F)=CC=C2NC=1SCC(N=CC=1)=CC=1OCC1CC1 KTXVWWXXGRAFKB-UHFFFAOYSA-N 0.000 description 4
ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
RFJGNWGMCBFYTP-UHFFFAOYSA-N methyl 2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-6-methyl-1h-benzimidazole-5-carboxylate Chemical compound N1C=2C=C(C)C(C(=O)OC)=CC=2N=C1S(=O)CC1=NC=CC(OC)=C1OC RFJGNWGMCBFYTP-UHFFFAOYSA-N 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 4
239000006188 syrup Substances 0.000 description 4
235000020357 syrup Nutrition 0.000 description 4
150000003608 titanium Chemical class 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 3
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 3
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 3
RKOTXQYWCBGZLP-UHFFFAOYSA-N N-[(2,4-difluorophenyl)methyl]-2-ethyl-9-hydroxy-3-methoxy-1,8-dioxospiro[3H-pyrido[1,2-a]pyrazine-4,3'-oxolane]-7-carboxamide Chemical compound CCN1C(OC)C2(CCOC2)N2C=C(C(=O)NCC3=C(F)C=C(F)C=C3)C(=O)C(O)=C2C1=O RKOTXQYWCBGZLP-UHFFFAOYSA-N 0.000 description 3
IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000001816 cooling Methods 0.000 description 3
JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
GFDHSPQGYGSEBJ-UHFFFAOYSA-N methyl 2-[(3,4-dimethoxypyridin-2-yl)methylsulfanyl]-6-methyl-1h-benzimidazole-5-carboxylate Chemical compound N1C=2C=C(C)C(C(=O)OC)=CC=2N=C1SCC1=NC=CC(OC)=C1OC GFDHSPQGYGSEBJ-UHFFFAOYSA-N 0.000 description 3
239000012044 organic layer Substances 0.000 description 3
YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
UUPITLNVYVCTFW-UHFFFAOYSA-N 1-[5-[(4,5-diphenyl-1h-imidazol-2-yl)sulfanyl]pentyl]-3,5-dimethylpyrazole Chemical compound N1=C(C)C=C(C)N1CCCCCSC1=NC(C=2C=CC=CC=2)=C(C=2C=CC=CC=2)N1 UUPITLNVYVCTFW-UHFFFAOYSA-N 0.000 description 2
BSXAHDOWMOSVAP-UHFFFAOYSA-N 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfanyl]-1h-benzimidazole Chemical compound COCCCOC1=CC=NC(CSC=2NC3=CC=CC=C3N=2)=C1C BSXAHDOWMOSVAP-UHFFFAOYSA-N 0.000 description 2
UKILEIRWOYBGEJ-UHFFFAOYSA-N 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfanyl]-1h-benzimidazole Chemical compound COC1=CC=NC(CSC=2NC3=CC(OC(F)F)=CC=C3N=2)=C1OC UKILEIRWOYBGEJ-UHFFFAOYSA-N 0.000 description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical class [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000007429 general method Methods 0.000 description 2
239000012071 phase Substances 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000000746 purification Methods 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
238000010898 silica gel chromatography Methods 0.000 description 2
239000012064 sodium phosphate buffer Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
JXOSPTBRSOYXGC-UHFFFAOYSA-N 1-Chloro-4-iodobutane Chemical compound ClCCCCI JXOSPTBRSOYXGC-UHFFFAOYSA-N 0.000 description 1
VCMADTQZCBWKAB-UHFFFAOYSA-N 1-benzylsulfanyl-4-methylbenzene Chemical compound C1=CC(C)=CC=C1SCC1=CC=CC=C1 VCMADTQZCBWKAB-UHFFFAOYSA-N 0.000 description 1
RRBFBYJYWDLUGR-UHFFFAOYSA-N 1-chloro-3-(3-chlorophenyl)sulfinylbenzene Chemical class ClC1=CC=CC(S(=O)C=2C=C(Cl)C=CC=2)=C1 RRBFBYJYWDLUGR-UHFFFAOYSA-N 0.000 description 1
HFOVHZUQZANCPI-UHFFFAOYSA-N 1-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfanyl]benzimidazole Chemical compound COC1=C(C)C=NC(CSC=2N(C3=CC=CC=C3N=2)OC)=C1C HFOVHZUQZANCPI-UHFFFAOYSA-N 0.000 description 1
AIABEETXTKSDLE-UHFFFAOYSA-J 2,3-dihydroxybutanedioate;titanium(4+) Chemical compound [Ti+4].[O-]C(=O)C(O)C(O)C([O-])=O.[O-]C(=O)C(O)C(O)C([O-])=O AIABEETXTKSDLE-UHFFFAOYSA-J 0.000 description 1
KIFPIAKBYOIOCS-UHFFFAOYSA-N 2-methyl-2-(trioxidanyl)propane Chemical compound CC(C)(C)OOO KIFPIAKBYOIOCS-UHFFFAOYSA-N 0.000 description 1
DJXCWHRLBUYJFH-UHFFFAOYSA-N 2-pyridin-2-ylsulfinyl-1h-benzimidazole Chemical class N=1C2=CC=CC=C2NC=1S(=O)C1=CC=CC=N1 DJXCWHRLBUYJFH-UHFFFAOYSA-N 0.000 description 1
GMTAWLUJHGIUPU-UHFFFAOYSA-N 4,5-diphenyl-1,3-dihydroimidazole-2-thione Chemical compound N1C(S)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 GMTAWLUJHGIUPU-UHFFFAOYSA-N 0.000 description 1
KDBQPLMPBDHVEC-UHFFFAOYSA-N 9-(1h-benzimidazol-2-ylsulfanyl)-4-methoxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridine Chemical class N=1C2=CC=CC=C2NC=1SC1CCCCC2=C1N=CC=C2OC KDBQPLMPBDHVEC-UHFFFAOYSA-N 0.000 description 1
JWMQOWBYKLZSPY-UHFFFAOYSA-N 9-(1h-benzimidazol-2-ylsulfinyl)-4-methoxy-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridine Chemical compound N=1C2=CC=CC=C2NC=1S(=O)C1CCCCC2=C1N=CC=C2OC JWMQOWBYKLZSPY-UHFFFAOYSA-N 0.000 description 1
GDVPKQONYOBALE-UHFFFAOYSA-N C1(=CC=CC=C1)C=1N=C(NC=1C1=CC=CC=C1)CSCC=1NC(=C(N=1)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)C=1N=C(NC=1C1=CC=CC=C1)CSCC=1NC(=C(N=1)C1=CC=CC=C1)C1=CC=CC=C1 GDVPKQONYOBALE-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
YSAVZVORKRDODB-UHFFFAOYSA-N Diethyl tartrate Chemical compound CCOC(=O)C(O)C(O)C(=O)OCC YSAVZVORKRDODB-UHFFFAOYSA-N 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical group [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000003699 antiulcer agent Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000008021 deposition Effects 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000003821 enantio-separation Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
MHAJPDPJQMAIIY-UHFFFAOYSA-M hydroperoxide group Chemical group [O-]O MHAJPDPJQMAIIY-UHFFFAOYSA-M 0.000 description 1
SIXIIKVOZAGHPV-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 1
229960003174 lansoprazole Drugs 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
229950007395 leminoprazole Drugs 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VHILIAIEEYLJNA-UHFFFAOYSA-N methyl p-tolyl sulfide Chemical compound CSC1=CC=C(C)C=C1 VHILIAIEEYLJNA-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229940063517 omeprazole sodium Drugs 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
229960005019 pantoprazole Drugs 0.000 description 1
IKNCGYCHMGNBCP-UHFFFAOYSA-N propan-1-olate Chemical compound CCC[O-] IKNCGYCHMGNBCP-UHFFFAOYSA-N 0.000 description 1
230000005588 protonation Effects 0.000 description 1
239000013014 purified material Substances 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
RRFCKCAQHRITRG-UHFFFAOYSA-N sodium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide;hydrate Chemical compound O.[Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RRFCKCAQHRITRG-UHFFFAOYSA-N 0.000 description 1
230000003335 steric effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
150000003899 tartaric acid esters Chemical class 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/28—Sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Plural Heterocyclic Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Catalysts (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

SK48-97A 1994-07-15 1995-07-03 Spôsob prípravy substituovaných sulfoxidov SK284059B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9402510A SE504459C2 (sv)	1994-07-15	1994-07-15	Förfarande för framställning av substituerade sulfoxider
PCT/SE1995/000818 WO1996002535A1 (fr)	1994-07-15	1995-07-03	Procede de synthese de sulfoxydes substitues

Publications (2)

Publication Number	Publication Date
SK4897A3 SK4897A3 (en)	1997-08-06
SK284059B6 true SK284059B6 (sk)	2004-09-08

Family

ID=20394753

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK48-97A SK284059B6 (sk)	1994-07-15	1995-07-03	Spôsob prípravy substituovaných sulfoxidov

Country Status (41)

Country	Link
US (1)	US5948789A (fr)
EP (1)	EP0773940B2 (fr)
JP (1)	JP3795917B2 (fr)
KR (1)	KR100356252B1 (fr)
CN (1)	CN1070489C (fr)
AR (1)	AR003443A1 (fr)
AT (1)	ATE242233T1 (fr)
AU (1)	AU688074B2 (fr)
BR (1)	BR9508292A (fr)
CA (1)	CA2193994C (fr)
CZ (1)	CZ297987B6 (fr)
DE (1)	DE69530987T3 (fr)
DK (1)	DK0773940T4 (fr)
DZ (1)	DZ1911A1 (fr)
EE (1)	EE03354B1 (fr)
EG (1)	EG24534A (fr)
ES (1)	ES2199998T5 (fr)
FI (2)	FI117672B (fr)
HR (1)	HRP950401B1 (fr)
HU (1)	HU226361B1 (fr)
IL (1)	IL114477A (fr)
IS (1)	IS1772B (fr)
MA (1)	MA23611A1 (fr)
MX (1)	MX9700358A (fr)
MY (1)	MY113180A (fr)
NO (1)	NO312101B1 (fr)
NZ (1)	NZ289959A (fr)
PL (1)	PL186342B1 (fr)
PT (1)	PT773940E (fr)
RU (1)	RU2157806C2 (fr)
SA (1)	SA95160294B1 (fr)
SE (1)	SE504459C2 (fr)
SI (1)	SI0773940T2 (fr)
SK (1)	SK284059B6 (fr)
TN (1)	TNSN95081A1 (fr)
TR (1)	TR199500861A2 (fr)
TW (1)	TW372971B (fr)
UA (1)	UA47409C2 (fr)
WO (1)	WO1996002535A1 (fr)
YU (1)	YU49475B (fr)
ZA (1)	ZA955724B (fr)

Families Citing this family (154)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6875872B1 (en)	1993-05-28	2005-04-05	Astrazeneca	Compounds
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
SE504459C2 (sv) *	1994-07-15	1997-02-17	Astra Ab	Förfarande för framställning av substituerade sulfoxider
US6699885B2 (en)	1996-01-04	2004-03-02	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en)	1996-01-04	2003-11-11	Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US6747155B2 (en)	1997-05-30	2004-06-08	Astrazeneca Ab	Process
SE510650C2 (sv)	1997-05-30	1999-06-14	Astra Ab	Ny förening
SE510643C2 (sv) *	1997-06-27	1999-06-14	Astra Ab	Termodynamiskt stabil omeprazol natrium form B
JP2002507996A (ja) *	1997-07-03	2002-03-12	デュポンファーマシューティカルズカンパニー	神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
SE9704183D0 (sv) *	1997-11-14	1997-11-14	Astra Ab	New process
US6096340A (en) *	1997-11-14	2000-08-01	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
US6174548B1 (en)	1998-08-28	2001-01-16	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
CA2320963A1 (fr) *	1998-01-30	1999-08-05	Sepracor, Inc.	Compositions et procedes d'utilisation du r-lansoprazole
JP2002512263A (ja) *	1998-04-30	2002-04-23	セプラコール，インク．	Ｓ−レイブプラゾール組成物及び方法
AU3870599A (en) *	1998-04-30	1999-11-16	Sepracor, Inc.	R-rabeprazole compositions and methods
US6365589B1 (en)	1998-07-02	2002-04-02	Bristol-Myers Squibb Pharma Company	Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US6733778B1 (en)	1999-08-27	2004-05-11	Andrx Pharmaceuticals, Inc.	Omeprazole formulation
CN1087739C (zh) *	1998-12-28	2002-07-17	中国科学院成都有机化学研究所	光学纯的苯并咪唑类抗消化性溃疡药物的包结拆分制备法
SE9900274D0 (sv)	1999-01-28	1999-01-28	Astra Ab	New compound
TWI275587B (en)	1999-06-17	2007-03-11	Takeda Chemical Industries Ltd	A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
ES2240113T3 (es)	1999-06-30	2005-10-16	Takeda Pharmaceutical Company Limited	Cristales de lansoprazol.
WO2001014366A1 (fr) *	1999-08-25	2001-03-01	Takeda Chemical Industries, Ltd.	Procede de preparation de derives optiquement actifs de sulfoxyde
US6780880B1 (en)	1999-08-26	2004-08-24	Robert R. Whittle	FT-Raman spectroscopic measurement
US6262085B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) *	1999-08-26	2001-11-13	Robert R. Whittle	Pharmaceutical formulations
US6369087B1 (en)	1999-08-26	2002-04-09	Robert R. Whittle	Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Pharmaceutical unit dosage form
US6262086B1 (en)	1999-08-26	2001-07-17	Robert R. Whittle	Pharmaceutical unit dosage form
US6326384B1 (en)	1999-08-26	2001-12-04	Robert R. Whittle	Dry blend pharmaceutical unit dosage form
US6312712B1 (en)	1999-08-26	2001-11-06	Robert R. Whittle	Method of improving bioavailability
US6268385B1 (en)	1999-08-26	2001-07-31	Robert R. Whittle	Dry blend pharmaceutical formulations
WO2001083473A1 (fr) *	2000-04-28	2001-11-08	Takeda Chemical Industries, Ltd.	Procede de production d'un derive de sulfoxide optiquement actif
KR100869677B1 (ko)	2000-05-15	2008-11-21	다케다 야쿠힌 고교 가부시키가이샤	결정의 제조방법
KR20080067713A (ko)	2000-05-15	2008-07-21	다케다 야쿠힌 고교 가부시키가이샤	결정의 제조방법
CA2775616C (fr)	2000-08-04	2013-09-17	Takeda Pharmaceutical Company Limited	Sels de benzimidazoles et leur application
PL399787A1 (pl) *	2000-12-01	2012-11-05	Takeda Pharmaceutical Company Ltd.	Krysztaly (R)- lub (S)-2-[[[3-metylo-4-(2,2,2-trifluoroetoksy)-2-pirydynylo]metylo]sulfinylo]-1H-benzimidazolu, kompozycja farmaceutyczna zawierajaca te krysztaly i ich zastosowanie
JP2004536049A (ja) *	2001-04-13	2004-12-02	アプシンターム・リミテッド・ライアビリティ・カンパニー	スルフィンアミドおよびスルホキシドの製造方法
GB2376231A (en) *	2001-06-06	2002-12-11	Cipla Ltd	Benzimidazole-cyclodextrin inclusion complex
CA2472103A1 (fr) *	2002-01-25	2003-08-07	Santarus, Inc.	Administration par voie muqueuse d'inhibiteurs de la pompe a protons
EP1487818B1 (fr) *	2002-03-05	2007-05-30	AstraZeneca AB	Sels d'alkylammonium d'omeprazole et d'esomeprazole
AU2003262375A1 (en) *	2002-04-22	2003-11-03	Sun Pharmaceutical Industries Limited	Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
WO2004002982A2 (fr) *	2002-06-27	2004-01-08	Dr. Reddy's Laboratories Limited	Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
MY148805A (en)	2002-10-16	2013-05-31	Takeda Pharmaceutical	Controlled release preparation
EP2596792A1 (fr)	2002-10-16	2013-05-29	Takeda Pharmaceutical Company Limited	Préparations solides stables
EA200500673A1 (ru)	2002-10-22	2005-12-29	Рэнбакси Лабораториз Лимитед	Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
DE10254167A1 (de)	2002-11-20	2004-06-09	Icon Genetics Ag	Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
EP1578742B1 (fr) *	2002-12-06	2012-10-17	Nycomed GmbH	Procede de preparation de composes actifs optiquement pures
DK1575941T3 (da) *	2002-12-06	2012-07-09	Nycomed Gmbh	Fremgangsmåde til fremstilling af (S)-pantoprazol
FR2848555B1 (fr)	2002-12-16	2006-07-28	Negma Gild	Enantiomere(-)du tenatoprazole et son application en therapeutique
WO2004055001A2 (fr) *	2002-12-16	2004-07-01	Ranbaxy Laboratories Limited	Calcium de rabeprazole
EP1572680A2 (fr)	2002-12-19	2005-09-14	Eva Pharmaceutical Industries Ltd.	États solides de sodium de pantoprazole et leurs procédés de préparation hydrates de sodium de pantoprazole connus
WO2004060263A2 (fr) *	2003-01-07	2004-07-22	Ranbaxy Laboratories Limited	Sels de magnesium de derives de l'imidazole
JP2006518751A (ja) *	2003-02-20	2006-08-17	サンタラスインコーポレイティッド	胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
CN1777598A (zh) *	2003-02-28	2006-05-24	兰贝克赛实验室有限公司	S－奥美拉唑的多晶型物
ES2245277T1 (es) *	2003-03-12	2006-01-01	Teva Pharmaceutical Industries Limited	Solidos cristalinos y amorfos de pantoprazol y procedimientos para su preparacion.
US7608625B2 (en) *	2003-03-13	2009-10-27	Eisai R & D Management Co., Ltd.	Method for treating bruxism and bruxism-related diseases
EP1608649A2 (fr) *	2003-03-28	2005-12-28	Sidem Pharma SA	Procede de preparation enantioselective de derives de sulfoxydes.
FR2852956B1 (fr) *	2003-03-28	2006-08-04	Negma Gild	Procede de preparation enantioselective de derives de sulfoxydes
CN1842525A (zh) *	2003-05-05	2006-10-04	兰贝克赛实验室有限公司	苯并咪唑衍生物的钡盐
WO2004111029A2 (fr)	2003-06-10	2004-12-23	Teva Pharmaceutical Industries Ltd.	Procede de preparation de benzimidazoles 2-[(pyridinyl)methyl]sulfinyle substitues et nouveau derives chlorures de pantoprazole
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
SE0302381D0 (sv)	2003-09-04	2003-09-04	Astrazeneca Ab	New salts I
SE0302382D0 (sv)	2003-09-04	2003-09-04	Astrazeneca Ab	New salts II
AU2003288703A1 (en) *	2003-12-05	2005-06-24	Hetero Drugs Limited	A process for the preparation of substitited pyridinylmethylsulfinyl- benzimidazole enantiomers
SE0400410D0 (sv) *	2004-02-20	2004-02-20	Astrazeneca Ab	New compounds
DE602004022337D1 (de)	2004-04-28	2009-09-10	Hetero Drugs Ltd	Verfahren zur herstellung von pyridinylmethyl-1h-benzimidazolverbindungen in enantiomerenangereicherter form oder als einzelne enantiomere
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602004025386D1 (de) *	2004-05-28	2010-03-18	Hetero Drugs Ltd	Neue stereoselektive synthese von benzimidazolsulfoxiden
EP1758889A1 (fr) *	2004-06-02	2007-03-07	Altana Pharma AG	Procede permettant la preparation de composes pyridin-2-yl-methyl-sulfinyl-1h-benzimidazol
AU2005264864B2 (en)	2004-06-16	2011-08-11	Takeda Pharmaceutical Company Limited	Multiple PPI dosage form
KR20130140918A (ko) *	2004-06-24	2013-12-24	아스트라제네카 아베	에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정 변형의 제조를 위한 신규한 방법
US20080249134A1 (en) *	2004-06-24	2008-10-09	Ursula Hohlneicher	New Esomeprazole Sodium Salt Crystal Modification
FR2876101B1 (fr) *	2004-10-05	2007-03-02	Sidem Pharma Sa Sa	Procede de preparation enantioselective de derives de sulfoxydes
EP1802584B1 (fr) *	2004-10-11	2009-09-16	Ranbaxy Laboratories Limited	Procedes de preparation de sulfoxydes substitues
US7592111B2 (en) *	2004-11-05	2009-09-22	Xerox Corporation	Imaging member
JP4837722B2 (ja) *	2005-03-25	2011-12-14	リブゾンファーマシューティカルグループインク．	置換スルホキシド化合物、その調製方法、およびその使用方法
CN101098867B (zh) *	2005-03-25	2010-08-11	丽珠医药集团股份有限公司	取代的亚砜类化合物和其制备方法及用途
US20090298884A1 (en) *	2005-05-06	2009-12-03	Glenmark Generics Ltd.	Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same
JP2008545768A (ja) *	2005-06-08	2008-12-18	レツク・フアーマシユーテイカルズ・デー・デー	オメプラゾールナトリウムの結晶性溶媒和物
US20070043085A1 (en) *	2005-08-19	2007-02-22	Glenmark Pharmaceuticals Limited	Process for the preparation of amorphous form of neutral esomeprazole
BRPI0619158A2 (pt) *	2005-12-05	2011-09-20	Astrazeneca Ab	processo para preparar forma que não que não seja sal de esomeprazol, composto, formulação farmacêutica, e, método de tratamento
EP1801110A1 (fr)	2005-12-22	2007-06-27	KRKA, tovarna zdravil, d.d., Novo mesto	Sel d'arginine d'ésoméprazole
DE102005061720B3 (de) *	2005-12-22	2006-10-19	Ratiopharm Gmbh	Enantioselektive Herstellung von Benzimidazolderivaten und ihren Salzen
US7553857B2 (en)	2005-12-23	2009-06-30	Lek Pharmaceuticals D.D.	S-omeprazole magnesium
ES2325336T3 (es)	2005-12-28	2009-09-01	Union Quimico-Farmaceutica, S.A.	Procedimiento para la preparacion del enantiomero (s) de omeprazol.
CN1810803B (zh) *	2006-02-17	2010-11-17	中国科学院上海有机化学研究所	高对映体选择性制备(s)-奥美拉唑的方法
US7579476B2 (en) *	2006-02-24	2009-08-25	Praktikatalyst Pharma, Llc	Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) *	2006-05-04	2011-11-22	Dr. Reddy's Laboratories Limited	Polymorphic forms of esomeprazole sodium
US7786309B2 (en) *	2006-06-09	2010-08-31	Apotex Pharmachem Inc.	Process for the preparation of esomeprazole and salts thereof
BRPI0621832A2 (pt)	2006-07-05	2013-03-19	Lupin Ltd	processo para a preparaÇço de enantiâmeros oticamente puros ou oticamente enriquecidos de compostos de sulfàxido
EP2054403A1 (fr) *	2006-08-08	2009-05-06	Jubilant Organosys Limited	Procédé de production de composés de sulfoxyde
JP2009196894A (ja) *	2006-10-13	2009-09-03	Eisai R & D Management Co Ltd	スルフィニルベンズイミダゾール化合物またはその塩の製造方法
JP5492417B2 (ja)	2006-10-13	2014-05-14	エーザイ・アール・アンド・ディー・マネジメント株式会社	胃酸分泌抑制作用を有するベンズイミダゾール化合物
EP1947099A1 (fr)	2007-01-18	2008-07-23	LEK Pharmaceuticals D.D.	Procédé pour l'élimination de solvant des sels d'oméprazole
WO2008102145A2 (fr)	2007-02-21	2008-08-28	Cipla Limited	Procédé pour la préparation de ésoméprazole magnésium dihydraté
RU2341524C1 (ru) *	2007-05-02	2008-12-20	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	СПОСОБ ПОЛУЧЕНИЯ ОПТИЧЕСКИ АКТИВНОГО 5-МЕТОКСИ-2-((4-МЕТОКСИ-3,5-ДИМЕТИЛПИРИДИН-2-ИЛ)МЕТИЛСУЛЬФИНИЛ)-1Н-БЕНЗО[d]ИМИДАЗОЛА
ATE534643T1 (de) *	2007-06-07	2011-12-15	Aurobindo Pharma Ltd	Verbessertes verfahren zur herstellung eines optisch aktiven protonenpumpenhemmers
CN101323609B (zh) *	2007-06-15	2013-05-01	成都福瑞生物工程有限公司	不对称氧化硫醚成亚砜合成对映体含量高的苯并咪唑衍生物的方法
US20100210848A1 (en) *	2007-10-03	2010-08-19	Ipca Laboratories Ltd.	Process for optically active sulfoxide compounds
WO2009047775A2 (fr)	2007-10-08	2009-04-16	Hetero Drugs Limited	Polymorphes de sels de l'ésoméprazole
EP2203068A4 (fr)	2007-10-12	2012-08-22	Takeda Pharmaceuticals Usa Inc	Procédés de traitement de troubles gastro-intestinaux indépendants de la prise alimentaire
FR2925899B1 (fr) *	2007-12-27	2012-12-21	Sidem Pharma Sa	Procede de preparation enantioselective de sulfoxydes.
CN101492459B (zh) *	2008-01-25	2011-04-27	山东轩竹医药科技有限公司	含烷氧乙酰基二氢异噁唑并吡啶化合物
CN101497603B (zh) *	2008-01-30	2012-11-07	山东轩竹医药科技有限公司	含有被烷氧烷胺氧基取代的吡啶的苯并咪唑衍生物
ES2638463T3 (es)	2008-03-10	2017-10-20	Takeda Pharmaceutical Company Limited	Cristal de compuesto de bencimidazol
CA2717578A1 (fr) *	2008-03-18	2009-09-24	Dr. Reddy's Laboratories Ltd.	Procede de preparation du dexlansoprazole et autres formes polymorphes
CN101538264A (zh) *	2008-03-19	2009-09-23	中国科学院成都有机化学有限公司	手性亚砜类化合物的制备新方法
WO2009145368A1 (fr) *	2008-05-27	2009-12-03	Sk Chemicals Co., Ltd.	Procédé amélioré de préparation de (s)-oméprazole à partir d'un racémate d'oméprazole à l’aide d'un agent de résolution optique
EP2143722A1 (fr)	2008-07-09	2010-01-13	Lek Pharmaceuticals D.D.	Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
US20100113527A1 (en) *	2008-09-30	2010-05-06	Teva Pharmaceutical Industries Ltd.	Crystalline forms of dexlansoprazole
EP2264024A1 (fr)	2008-10-14	2010-12-22	LEK Pharmaceuticals d.d.	Procédé de préparation d'inhibiteurs de la pompe à protons énantiomériquement enrichis
IT1391776B1 (it)	2008-11-18	2012-01-27	Dipharma Francis Srl	Procedimento per la preparazione di dexlansoprazolo
CZ200990A3 (cs) *	2009-02-16	2010-08-25	Zentiva, K.S.	Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010097583A1 (fr)	2009-02-24	2010-09-02	Cipla Limited	Polymorphe de l'ésoméprazole de potassium et sa préparation
CZ2009172A3 (cs) *	2009-03-17	2010-09-29	Zentiva, K.S.	Zpusob výroby (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazolu
WO2010150276A2 (fr) *	2009-06-02	2010-12-29	Sun Pharmaceutical Industries Limited	Procédé d'élaboration de composés sulfoxyde
IT1395118B1 (it)	2009-07-29	2012-09-05	Dipharma Francis Srl	Procedimento per la preparazione di dexlansoprazolo cristallino
WO2011058569A1 (fr)	2009-11-12	2011-05-19	Hetero Research Foundation	Procédé de dédoublement de l'oméprazole
CA2788147A1 (fr)	2010-01-29	2011-08-04	Ranbaxy Laboratories Limited	Procede pour la preparation de formes cristallines de dexlansoprazole
EP2585450A1 (fr)	2010-06-24	2013-05-01	Cilpa Limited	Sels et polymorphes de la dexrabéprazole
CN101914090B (zh) *	2010-08-13	2013-03-20	埃斯特维华义制药有限公司	左旋奥美拉唑的制备方法
CN102558150B (zh) *	2010-12-31	2014-03-12	正大天晴药业集团股份有限公司	取代亚砜化合物的合成方法
CN102321071B (zh) *	2011-07-20	2013-01-23	江苏奥赛康药业股份有限公司	一种高纯度埃索美拉唑钠的工业化生产方法
CN102977076A (zh) *	2011-09-02	2013-03-20	扬子江药业集团上海海尼药业有限公司	一种右兰索拉唑的制备方法
CN102329302A (zh) *	2011-10-22	2012-01-25	刘强	一种埃索美拉唑及其盐的制备方法
CN102408412A (zh) *	2011-10-25	2012-04-11	广东华南药业集团有限公司	高对映体选择性制备（s）- 奥美拉唑的方法
CN102432412A (zh) *	2011-10-28	2012-05-02	成都欣捷高新技术开发有限公司	一种手性亚砜类质子泵抑制剂或其可药用盐的制备方法
KR101300950B1 (ko) *	2011-10-31	2013-08-27	르노삼성자동차 주식회사	전기자동차의 공기 흡입 장치
WO2013140120A1 (fr)	2012-03-22	2013-09-26	Cipla Limited	Formes solvatées de glycérol de (r)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl]sulphinyl]-lh-benzimidazole
CN102633776B (zh) *	2012-03-28	2014-06-18	中山市仁合药业有限公司	一种埃索美拉唑及其钠盐的制备方法
CN102659763B (zh) *	2012-04-27	2014-01-22	南京优科生物医药研究有限公司	一种右旋兰索拉唑合成与纯化的方法
CN103044402B (zh) *	2012-12-31	2015-01-14	康普药业股份有限公司	埃索美拉唑钠合成生产方法
CN103113351B (zh) *	2013-03-08	2015-01-21	苏州特瑞药业有限公司	一种光学纯手性亚砜类化合物的制备方法
CN104177336A (zh) *	2013-05-28	2014-12-03	上海汇伦生命科技有限公司	一种对映选择性合成右兰索拉唑的方法
EP2929885A1 (fr)	2014-04-11	2015-10-14	Sanovel Ilac Sanayi ve Ticaret A.S.	Combinaisons pharmaceutiques de rivaroxaban et d'inhibiteurs de la pompe à protons
EP2933002A1 (fr)	2014-04-11	2015-10-21	Sanovel Ilac Sanayi ve Ticaret A.S.	Compositions pharmaceutiques comprenants de dabigratan et des inhibiteurs de la pompe à protons
EP2980086B1 (fr)	2014-07-29	2016-06-15	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé efficace pour la préparation d'ésoméprazole (S)-binol complexe
WO2016104668A1 (fr) *	2014-12-26	2016-06-30	国立大学法人東京大学	Procédé de fabrication d'un composé inhibiteur de la pompe à protons ayant une activité optique
CN104610226A (zh) *	2014-12-31	2015-05-13	广东东阳光药业有限公司	一种右兰索拉唑的不对称氧化方法
ES2615637T3 (es) *	2015-03-06	2017-06-07	F.I.S.- Fabbrica Italiana Sintetici S.P.A.	Procedimiento mejorado para la purificación óptica del esomeprazol
CN105218392B (zh) *	2015-07-09	2017-11-21	天津青松华药医药有限公司	D‑酒石酸单酯单酰胺类化合物
CN105218391B (zh) *	2015-07-09	2017-11-21	天津青松华药医药有限公司	L‑酒石酸单酯单酰胺类化合物
CN105968097B (zh) *	2016-05-17	2019-05-03	杭州华东医药集团新药研究院有限公司	左旋泮托拉唑的工业化生产方法
CN106083818A (zh) *	2016-06-08	2016-11-09	扬子江药业集团有限公司	一种高纯度埃索美拉唑钠的制备方法
CN106366070B (zh) *	2016-08-10	2019-06-11	上海万巷制药有限公司	一种高纯度埃索美拉唑钠的制备方法
CN106632248A (zh) *	2016-09-30	2017-05-10	青岛云天生物技术有限公司	一种左旋泮托拉唑钠的制备工艺
CN106632249A (zh) *	2016-09-30	2017-05-10	青岛云天生物技术有限公司	一种制备(s)‑泮托拉唑钠的方法
CN106866630B (zh) *	2017-04-01	2018-08-07	上海华源医药科技发展有限公司	一种右兰索拉唑的制备方法
CN110698482A (zh) *	2019-10-29	2020-01-17	株洲千金药业股份有限公司	一种s型手性亚砜类化合物的制备方法
CN110746428A (zh) *	2019-10-29	2020-02-04	株洲千金药业股份有限公司	一种r型手性亚砜类化合物的制备方法
CN113845510B (zh) *	2020-06-27	2025-02-18	鲁南制药集团股份有限公司	一种埃索美拉唑的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
JPS6150978A (ja) *	1984-08-16	1986-03-13	Takeda Chem Ind Ltd	ピリジン誘導体およびその製造法
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
SE9002206D0 (sv) *	1990-06-20	1990-06-20	Haessle Ab	New compounds
DE4035455A1 (de) *	1990-11-08	1992-05-14	Byk Gulden Lomberg Chem Fab	Enantiomerentrennung
WO1993006037A1 (fr) *	1991-09-16	1993-04-01	Catalytica, Inc.	Procede et catalyseur de production de brome
CA2136993A1 (fr) *	1992-06-01	1993-12-09	Takeshi Kawakita	Compose de la pyridine et son utilisation pharmaceutique
SE9301830D0 (sv) *	1993-05-28	1993-05-28	Ab Astra	New compounds
SE504459C2 (sv) *	1994-07-15	1997-02-17	Astra Ab	Förfarande för framställning av substituerade sulfoxider
GB9423968D0 (en) *	1994-11-28	1995-01-11	Astra Ab	Resolution
GB9423970D0 (en) *	1994-11-28	1995-01-11	Astra Ab	Oxidation

1994
- 1994-07-15 SE SE9402510A patent/SE504459C2/sv not_active IP Right Cessation
1995
- 1995-07-03 DK DK95926068.8T patent/DK0773940T4/da active
- 1995-07-03 MX MX9700358D patent/MX9700358A/es unknown
- 1995-07-03 DE DE69530987T patent/DE69530987T3/de not_active Expired - Lifetime
- 1995-07-03 RU RU97102162/04A patent/RU2157806C2/ru active
- 1995-07-03 SI SI9530676T patent/SI0773940T2/sl unknown
- 1995-07-03 UA UA97020638A patent/UA47409C2/uk unknown
- 1995-07-03 KR KR1019970700221A patent/KR100356252B1/ko not_active Expired - Lifetime
- 1995-07-03 US US08/492,087 patent/US5948789A/en not_active Expired - Lifetime
- 1995-07-03 AU AU29948/95A patent/AU688074B2/en not_active Expired
- 1995-07-03 BR BR9508292A patent/BR9508292A/pt not_active Application Discontinuation
- 1995-07-03 ES ES95926068T patent/ES2199998T5/es not_active Expired - Lifetime
- 1995-07-03 CA CA002193994A patent/CA2193994C/fr not_active Expired - Lifetime
- 1995-07-03 WO PCT/SE1995/000818 patent/WO1996002535A1/fr active Search and Examination
- 1995-07-03 SK SK48-97A patent/SK284059B6/sk not_active IP Right Cessation
- 1995-07-03 AT AT95926068T patent/ATE242233T1/de active
- 1995-07-03 EP EP95926068A patent/EP0773940B2/fr not_active Expired - Lifetime
- 1995-07-03 PT PT95926068T patent/PT773940E/pt unknown
- 1995-07-03 EE EE9700006A patent/EE03354B1/xx unknown
- 1995-07-03 JP JP50493896A patent/JP3795917B2/ja not_active Expired - Fee Related
- 1995-07-04 TW TW084106875A patent/TW372971B/zh not_active IP Right Cessation
- 1995-07-05 CZ CZ0006497A patent/CZ297987B6/cs not_active IP Right Cessation
- 1995-07-05 PL PL95318165A patent/PL186342B1/pl unknown
- 1995-07-05 CN CN95194956.XA patent/CN1070489C/zh not_active Expired - Lifetime
- 1995-07-05 HU HU9700108A patent/HU226361B1/hu unknown
- 1995-07-05 NZ NZ289959A patent/NZ289959A/en not_active IP Right Cessation
- 1995-07-06 IL IL11447795A patent/IL114477A/en not_active IP Right Cessation
- 1995-07-10 MA MA23950A patent/MA23611A1/fr unknown
- 1995-07-10 ZA ZA955724A patent/ZA955724B/xx unknown
- 1995-07-11 DZ DZ950088A patent/DZ1911A1/fr active
- 1995-07-11 EG EG57195A patent/EG24534A/xx active
- 1995-07-12 HR HR950401A patent/HRP950401B1/xx not_active IP Right Cessation
- 1995-07-13 TN TNTNSN95081A patent/TNSN95081A1/fr unknown
- 1995-07-14 TR TR95/00861A patent/TR199500861A2/xx unknown
- 1995-07-14 YU YU47695A patent/YU49475B/sh unknown
- 1995-07-14 MY MYPI95001998A patent/MY113180A/en unknown
- 1995-10-07 SA SA95160294A patent/SA95160294B1/ar unknown
1996
- 1996-06-28 AR ARP960103398A patent/AR003443A1/es active IP Right Grant
- 1996-12-27 IS IS4406A patent/IS1772B/is unknown
1997
- 1997-01-10 FI FI970102A patent/FI117672B/fi not_active IP Right Cessation
- 1997-01-10 FI FI970102D patent/FI117830B/fi active
- 1997-01-14 NO NO19970153A patent/NO312101B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
BR9508292A (pt)	1997-12-23
FI117830B (fi)	2007-03-15
SA95160294B1 (ar)	2006-07-31
HU226361B1 (en)	2008-09-29
MA23611A1 (fr)	1996-04-01
SI0773940T2 (sl)	2011-02-28
SI0773940T1 (en)	2004-02-29
SE9402510L (sv)	1996-01-16
ATE242233T1 (de)	2003-06-15
NO970153D0 (no)	1997-01-14
SE504459C2 (sv)	1997-02-17
HK1008331A1 (en)	1999-05-07
AR003443A1 (es)	1998-08-05
DZ1911A1 (fr)	2002-02-17
AU2994895A (en)	1996-02-16
CA2193994A1 (fr)	1996-02-01
IS1772B (is)	2001-06-01
IS4406A (is)	1996-12-27
IL114477A0 (en)	1995-11-27
UA47409C2 (uk)	2002-07-15
EG24534A (en)	2009-08-30
PL186342B1 (pl)	2003-12-31
CN1070489C (zh)	2001-09-05
NO312101B1 (no)	2002-03-18
RU2157806C2 (ru)	2000-10-20
IL114477A (en)	2001-07-24
KR970704731A (ko)	1997-09-06
AU688074B2 (en)	1998-03-05
JPH10504290A (ja)	1998-04-28
NO970153L (no)	1997-01-14
TNSN95081A1 (fr)	1996-02-06
SE9402510D0 (sv)	1994-07-15
HUT76642A (en)	1997-10-28
JP3795917B2 (ja)	2006-07-12
YU49475B (sh)	2006-05-25
ZA955724B (en)	1996-01-15
US5948789A (en)	1999-09-07
WO1996002535A8 (fr)	1999-12-23
DK0773940T3 (da)	2003-09-15
WO1996002535A1 (fr)	1996-02-01
DE69530987T2 (de)	2004-05-19
DE69530987T3 (de)	2011-07-07
HRP950401A2 (en)	1997-10-31
KR100356252B1 (ko)	2002-11-18
TR199500861A2 (tr)	1996-06-21
ES2199998T3 (es)	2004-03-01
EE03354B1 (et)	2001-02-15
MX9700358A (es)	1997-04-30
EP0773940B2 (fr)	2010-11-17
HRP950401B1 (en)	2004-04-30
CZ297987B6 (cs)	2007-05-16
SK4897A3 (en)	1997-08-06
DE69530987D1 (de)	2003-07-10
DK0773940T4 (da)	2011-02-07
FI970102L (fi)	1997-01-10
EP0773940A1 (fr)	1997-05-21
FI117672B (fi)	2007-01-15
PT773940E (pt)	2003-10-31
NZ289959A (en)	1998-01-26
MY113180A (en)	2001-12-31
CA2193994C (fr)	2005-05-03
ES2199998T5 (es)	2011-03-16
YU47695A (sh)	1998-07-10
FI970102A0 (fi)	1997-01-10
EP0773940B1 (fr)	2003-06-04
TW372971B (en)	1999-11-01
CZ6497A3 (en)	1997-06-11
PL318165A1 (en)	1997-05-26
CN1157614A (zh)	1997-08-20

Legal Events

Date	Code	Title	Description
2015-09-03	MK4A	Patent expired	Expiry date: 20150703

Publication	Publication Date	Title
SK284059B6 (sk)	2004-09-08	Spôsob prípravy substituovaných sulfoxidov
CA2226184C (fr)	2008-08-05	Procede de purification optique pour derives de benzimidazole enrichis par enantiomorphe
US7452998B2 (en)	2008-11-18	Process for preparing optically pure active compounds
CA2507889C (fr)	2012-02-07	Procede de preparation de (s)-pantoprazole
HK1008331B (en)	2003-11-21	Process for synthesis of substituted sulphoxides
MXPA98000160A (en)	1998-10-15	A process for the optic purification of derivatives of benzimidazol enriquecidos enantiomericame
HK1010193B (en)	2009-04-17	A process for the optical purification of enantiomerically enriched benzimidazole derivatives